Bookmark Us
All Food, Diet and Health News 
 Misc. News
 Must-Read News
 Letter to Editor
 Featured Products
 Recalls & Alerts
 Consumer Affair
 Non-food Things
 Health Tips
 Interesting Sites
 Diet & Health
 Heart & Blood
 Body Weight
 Children & Women
 General Health
 Food & Health
 Food Chemicals
 Biological Agents
 Cooking & Packing
 Agri. & Environ.
 Laws & Politics
 General Health
 Drug News
 Mental Health
 Infectious Disease
 Other News
 Food Consumer
 FC News & Others

Search Foodconsumer & Others

Add to Google
Add to My Yahoo
Newsfeed news feed
Su bmit news[release]

More than 100 credit cards available at from, you can pick more than 100 credit cards

Misc. News : Non-food Things Last Updated: Apr 20, 2011 - 9:38:09 AM

FDA warns drugmakers of tainted additive
By Sue Mueller
May 7, 2007 - 6:35:28 AM

E.mail t.his a.rticle
 P.rinter f.riendly p.age
Get n.ewsletter

The Food and Drug Administration on May 4 issued a advisory to warn drugmakers, suppliers and health professionals that a counterfeit additive may be illegally used to replace or contaminate more expensive glycerin, a sweet syrup used in over-the-counter medicine like cough medications, fever medication and injectable drugs.


The FDA suggests, but not requires that drug manufacturers test glycerin for possible contamination of diethylene glycol or DEG, a known poison that is used in antifreeze and as a solvent.


No evidence indicates that glycerin used in the US has been tainted with the poisonous industrial solvent, the FDA says.   But caution needs to be excised to ensure glycerin used in the country is free of DEG.


The warning was issued as cases of death associated with use of tainted glycerin have been reported to the FDA since last October. Panama has recently confirmed 100 deaths from the DEG contamination and another 200 are waiting to be confirmed.


Today, the New York Times reported in a lengthy article that the DEG responsible for the deaths in Panama probably originated from some Chinese suppliers.   Although it can't be 100 percent certain, the newspaper found that some chemical traders often sell industrial grade DEG as 95.5 percent pure glycerin to make a ludicrous profit.   


Inhalation of diethylene glycol can cause cough and dizziness and contact with it can lead to redness on the skin and the eyes. Ingestion of the poison causes abdominal pain; confusion; dizziness; downiness; nausea; unconsciousness; and vomiting. In serious cases, it can cause kidney failure and nervous damage or even deaths.


In Haiti, 85 children died in 1996 through glycerin contaminated with DEG in paracetamol syrup produced by Pharval Laboratories, a Haitian company, which did not verify the authenticity of the glycerin supplied by a Dutch company, Vos from a manufacturer in China, according to Wikipedia.


In October 20006, the Centers for Disease Control and Prevention and the Ministry of health of Panama found toxic levels of diethylene glycol in a sugarless liquid expectorant during an investigation of 46 deaths from a syndrome characterized by gastrointestinal symptoms, renal failure and paralysis.


Between 1990 and 1998, according to the FDA, similar incidents of DEG poisoning reportedly occurred in Argentina, Bangladesh, India, and Nigeria and resulted in hundreds of deaths.


In the US, the FDA says, more than 100 people died in 1937 after ingesting DEG-contaminated Elixir Sulfanilamide, a drug used to treat infections, which triggered the enactment of the Federal Food, Drug, and Cosmetic Act. However, no death in the country has been linked to DEG contamination in any medicine.


The FDA says that it "is emphasizing the importance of testing glycerin for DEG due to the serious nature of this potentially fatal problem in combination with the global nature of the pharmaceutical supply chain and problems that continue to occur with this kind of contamination in some parts of the global supply of glycerin."



The FDA recommends that:



1.    Drug product manufacturers perform a specific identity test that includes a limit test for DEG on all containers of all lots of glycerin before the glycerin is used in the manufacture or preparation of drug products because of the serious hazard associated with DEG contamination.3.    The relevant safety limit for DEG is 0.1%, as recognized by the USP monograph for glycerin.   The Agency recommends that a manufacturer perform the identity tests, including the limit test for DEG, which appear in the USP monograph for glycerin.    Alternatively, a manufacturer may use an equivalent identification procedure that includes a test to detect and quantify DEG provided it meets the relevant safety limit.   One alternative procedure is a thin-layer chromatography (TLC) method published in the Journal of AOAC International. 4.   


      This identification test is done in accordance with the CGMPs, which require that each lot of a component undergo testing to confirm its identity before use in drug product manufacturing (21 CFR 211.84(d)(1) requires that “[a]t least one test shall be conducted to verify the identity of each component of a drug product.   Specific identity tests, if they exist, shall be used”).   A specific identity test for glycerin is found in the United States Pharmacopeia (USP) monograph. 5.    The USP monograph for glycerin provides a two-part identity test:   test A using “Infrared Absorption” and test B using gas chromatography that references the “Limit of Diethylene Glycol and Related Compounds.”   The infrared absorption test identifies glycerin and DEG, but does not distinguish between the two.   Test B distinguishes glycerin from DEG. 6.


2.    Drug product manufacturers know their supply chain for glycerin (i.e., the manufacturer of the component and any subsequent distributor(s)).


3.    All manufacturers take every opportunity to ensure proper testing of glycerin for DEG contamination.   All personnel in pharmaceutical manufacturing facilities (especially personnel directly responsible for receipt, testing, and release of glycerin) should be made aware of the importance of proper testing and the potential hazards if the testing is not done.


4.    Repackers, and others who distribute and prepare glycerin for use in drug products, test glycerin that is used, sold for use, or intended for use in drug products.


5.    Pharmacies that use glycerin in compounding drug products either test the glycerin for DEG content or ensure that such testing was properly done by a reliable supplier.


Bulk or repackaged glycerin intended as an excipient or other component of a drug product is a drug as defined by section 201(g)(1) the Act (21 U.S.C. 321(g)(1)).   Section 501(a)(2)(B) of the Act (21 U.S.C. 351(a)(2)(B)) requires that the methods used in, or the facilities or controls used for a drug’s manufacture, processing, packing, or holding conform to CGMP.   Testing bulk or repackaged glycerin for DEG content is consistent with good manufacturing practice required under the Act.  


For other components, such as propylene glycol, that in the past were found to be contaminated with DEG, precautions should also be taken to identify reliable suppliers and secure shipment to prevent similar occurrences. 7.


© 2004-2008 by unless otherwise specified

Top of Page


Search Consumer-friendly Health Sites

We have moved to Food Consumer . Org

disclaimer | advertising | jobs | privacy | about us | newsletter | Submit news/articles
link partners: | Buy Viagra | |
Buy a home | Auto Insurance | Mortgage refinancing | | Take Your Blog to a Higher Level
© Copyright 2004 - 2008 All rights reserved

Disclaimer: What's published on this website should be considered opinions of respective writers only and which has no political agenda nor commercial ambition may or may not endorse any opinion of any writer. No accuracy is guaranteed although writers are doing their best to provide accurate information only. The information on this website should not be construed as medical advice and should not be used to replace professional services provided by qualified or licensed health care workers. The site serves only as a platform for writers and readers to share knowledge, experience, and information from the scientific community, organizations, government agencies and individuals. encourages readers who have had medical conditions to consult with licensed health care providers - conventional and or alternative medical practitioners.